Aberrations in the Fragile Histidine Triad (FHIT) gene may be involved in lung carcinogenesis in patients with chronic pulmonary tuberculosis

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 270-275

  Song, Lanying ^a   Yan, Wensheng ^b   Deng, Min ^a   Song, Shilin ^a   Zhang, Jinhua ^a   Zhao, Tong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

FHIT gene; Hyperplasia; Loss of heterozygosity; Lung cancer; Pulmonary tuberculosis

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; LUNG RESECTION; LUNG TUBERCULOSIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 11444259603     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081391     Document Type: Article

References (19)

1. Rybacka-Chabros B, Mandziuk S, Berger-Lukasiewicz A, Danko-Mrozinska M, Milanowski J: The coexistence of tuberculosis infection and lung cancer in patients treated in pulmonary department of Medical Academy in Lublin during last ten years (1990-2000). Folia Histochem Cytobiol 2001;39:73-74.
2. Brenner AV, Wang Z, Kleinerman RA, Wang L, Zhang S, Metayer C, Chen K, Lei S, Cui H, Lubin JH: Previous pulmonary disease and risk of lung cancer in Gansu province, China. Int J Epidemiol 2001;30:118-124.
3. Le CH, Ko YC, Cheng LS, Lin YC, Lin HJ, Huang MS, Huang JJ, Kao EL, Wang HZ: The heterogeneity in risk factors of lung cancer and the difference of histologic distribution between genders in Taiwan. Cancer Causes Control 2001;12:289-300.
4. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF: FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-2267.
5. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
6. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-5037.
7. Chang YL, Wu CT, Shih JY, Lee YC: Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers. Br J Cancer 2003;89:320-326.
8. Ginestier C, Bardou VJ, Popovici C, Charafe-Jauffret E, Bertucci F, Geneix J, Adelaide J, Chaffanet M, Hassoun J, Viens P, Jacquemier J, Birnbaum D: Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. Int J Cancer 2003;107:854-862.
9. Mineta H, Miura K, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Ito M, Wennerberg J: Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol 2003;39/1:56-63.
10. Mimori K, Inoue H, Shiraishi T, Matsuyama A, Mafune K, Tanaka Y, Mori M: Microsatellite instability is often observed in esophageal carcinoma patients with allelic loss in the FHIT/FRA3B locus. Oncology 2003;64/3:275-279.
11. Rocco A, Schandl L, Chen J, Wang H, Tulassay Z, McNamara D, Malfertheiner P, Ebert MP: Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 2003;129:84-88.
12. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K: Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-4836.
13. Sukosd F, Kuroda N, Beothe T, Kaur AP, Kovacs G: Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 2003;63:455-457.
14. Terry G, Ho L, Londesborough P, Cuzick J: Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions. Br J Cancer 2002;86:376-381.
15. Hao XP, Willis JE, Pretlow TG, Rao JS, Mac-Lennan GT, Talbot IC, Pretlow TP: Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000;60:18-21.
16. Moskaluk CA, Kern SE: Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol 1997;150:1547-1552.
17. Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, Gazdar AF: Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999;91:1863-1868.
18. Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K, Nomura T: Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer Res 1998;58:1105-1107.
19. Uematsu K, Yoshimura A, Gemma A, Mochimaru H, Hosoya Y, Kunugi S, Matsuda K, Seike M, Kurimoto F, Takenaka K, Koizumi K, Fukuda Y: Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 2001;61:8527-8533.